Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
QsL4Aw6QCsVxpZcp
Listen
